Compatibility Studies of Sildenafil-HPBCD Inclusion Complex with Pharmaceutical Excipients
Pharmaceutics · 27.08.2025 · 17 (9) · 1114
DOI: 10.3390/pharmaceutics17091114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 27.08.2025. Verfasst von Răzvan Adrian Bertici und 11 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School, "Victor Babeş" University of Medicine and Pharmacy Timișoara, Eftimie Murgu Square No. 2, 300041 Timișoara, Romania. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY TIMISOARA.
Abstract (Originalsprache)
Background/Objectives: In the past two decades, the primary therapeutic use of sildenafil has shifted significantly, from the treatment of angina to managing erectile dysfunction, and since the early 2000s it has been used in the treatment of pulmonary hypertension, particularly pulmonary arterial hypertension. Sildenafil is used as a citrate salt; after oral administration, it presents an absorption of ~90% and an absolute bioavailability of 38%, due to the first-pass effect, such that it belongs to class II of the Biopharmaceutics Classification System. Currently, studies are seeking to obtain new pharmaceutical formulations with an optimized biopharmaceutical profile. In this study, an inclusion complex of sildenafil citrate and 2-hydroxypropyl-beta-cyclodextrin in a molar ratio of 1:1 was obtained and its pharmaceutical compatibility with six pharmaceutical excipients was assessed. For three of these excipients, the presence of chemical interactions with sildenafil citrate has been presented in the literature, and for the other three, compatibility has not been evaluated.
Methods
To certify the stoichiometry of the obtained inclusion complex molecular modeling, Job’s method and the Benesi–Hildebrand method were employed. Furthermore, we have described the inclusion complex and the obtained binary mixtures via ATR-FTIR and thermal (TG/DTG and DSC) analysis.
Results
The results indicated a lack of chemical interactions between the inclusion complex and the six pharmaceutical excipients at ambient temperature (confirmed by ATR–FTIR investigations) and the presence of chemical interactions between the inclusion complex and three of the excipients when the mixture was heated under non-isothermal conditions (TG/DTG and DSC investigations).
Conclusions
This study describes the inclusion complex between sildenafil citrate and 2-hydroxypropyl-beta-cyclodextrin in a molar ratio of 1:1 and its compatibility with several pharmaceutical excipients, results with further applications in the preformulation stage of novel delivery systems.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Doctoral School, "Victor Babeş" University of Medicine and Pharmacy Timișoara, Eftimie Murgu Square No. 2, 300041 Timișoara, Romania.
- Center for Research and Innovation in Personalised Medicine of Respiratory Diseases, Pulmonology University Clinic, "Victor Babeș" University of Medicine and Pharmacy Timișoara, Eftimie Murgu Square No. 2, 300041 Timișo…
- Department of Analytical Chemistry, Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy Timișoara, Eftimie Murgu Square No. 2, 300041 Timișoara, Romania.
- Advanced Instrumental Screening Center, Faculty of Pharmacy, "Victor Babeş" University of Medicine and Pharmacy Timișoara, Eftimie Murgu Square No. 2, 300041 Timișoara, Romania.
- Pulmonary Hypertension Treatment Unit, Center of Expertise for Adult Rare Respiratory Diseases, Clinical Hospital of Infectious Diseases and Pneumophthisiology "Dr. Victor Babes", 13 Gheorghe Adam Str., 300310 Timișoara…
- Department of Physical Chemistry, Faculty of Pharmacy, "Victor Babeș" University of Medicine and Pharmacy Timișoara, Eftimie Murgu Square No. 2, 300041 Timișoara, Romania.
ORCID-Profile: Amalia Ridichie, Nicoleta Sorina Bertici, Adriana Ledeţi, Ionuţ Ledeţi, Laura Sbârcea, Gerlinde Rusu, Dragoș Cătălin Jianu, Ovidiu Fira-Mladinescu
Förderung
- VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY TIMISOARA
Zitieren
APA
Bertici, R. A., Ridichie, A., Bertici, N. S., Ledeţi, A., Ledeţi, I., Văruţ, R. M., Sbârcea, L., Albu, P., Rădulescu, M., Rusu, G., Jianu, D. C., & Fira-Mladinescu, O. (2025). Compatibility Studies of Sildenafil-HPBCD Inclusion Complex with Pharmaceutical Excipients. Pharmaceutics, 17(9), 1114. https://doi.org/10.3390/pharmaceutics17091114
Vancouver
Bertici RA, Ridichie A, Bertici NS, Ledeţi A, Ledeţi I, Văruţ RM, et al. Compatibility Studies of Sildenafil-HPBCD Inclusion Complex with Pharmaceutical Excipients. Pharmaceutics. 2025;17(9):1114. doi:10.3390/pharmaceutics17091114
BibTeX
@article{Bertici2025,
author = {Bertici, Răzvan Adrian and Ridichie, Amalia and Bertici, Nicoleta Sorina and Ledeţi, Adriana and Ledeţi, Ionuţ and Văruţ, Renata-Maria and Sbârcea, Laura and Albu, Paul and Rădulescu, Matilda and Rusu, Gerlinde and Jianu, Dragoș Cătălin and Fira-Mladinescu, Ovidiu},
title = {Compatibility Studies of Sildenafil-HPBCD Inclusion Complex with Pharmaceutical Excipients},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {9},
pages = {1114},
doi = {10.3390/pharmaceutics17091114}
}
EUVIMED